Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,585 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07617727 | A Phase I Study of JSKN021 in Advanced Solid Tumors | recruiting | Phase 1 | 199 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07744243 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07763639 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07778862 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787520 | A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors | not yet recruiting | Phase 1 | 150 | Laekna LimitedINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 70 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05460767 | Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma | active not recruiting | Phase 1 | 504 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05718219 | Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors | terminated | Phase 1 | 49 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07610148 | A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants | active not recruiting | Phase 1 | 21 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07783815 | A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure | not yet recruiting | Phase 1 | 20 | Xiangya Hospital of Central South UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784309 | A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies | enrolling by invitation | Phase 1 | 13 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02992210 | Study on GD2 Positive Solid Tumors by 4SCAR-GD2 | not yet recruiting | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03125577 | Combination CAR-T Cell Therapy Targeting Hematological Malignancies | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03159364 | Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | terminated | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03184753 | Genetically Modified T Cells Against Ovarian Cancer | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03185468 | Intervention of Bladder Cancer by CAR-T | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03356795 | Intervention of CAR-T Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03362606 | Engineered Immune Effectors Against Ovarian Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03362619 | Engineered Immune Effectors Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03535246 | Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04010877 | Multiple CAR-T Cell Therapy Targeting AML | terminated | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04085159 | Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04427449 | 4SCAR-CD44v6 T Cell Therapy Targeting Cancer | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04430530 | 4SCAR-T Therapy Post CD19-targeted Immunotherapy | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05262673 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | terminated | Phase 1 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05277753 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | terminated | Phase 1 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05436509 | CD19/79b Bi-specific CAR-T Cell Therapy | terminated | Phase 1 / Phase 2 | 60 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05437328 | GD2/CD56 Bi-specific CAR-T Cell Therapy | terminated | Phase 1 / Phase 2 | 60 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05437341 | PSMA/CD70 Bi-specific CAR-T Cell Therapy | terminated | Phase 1 / Phase 2 | 60 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06417554 | A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT06803680 | A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 90 | BeOne MedicinesINDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT07068555 | Prostate Cancer Vaccines | terminated | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07193966 | NG2 and DLL3 CAR-T Cells Targeting Melanoma | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07676903 | A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors | recruiting | Phase 1 | 170 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 479 | AmgenINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | recruiting | Phase 1 / Phase 2 | 146 | BeiGeneINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | recruiting | Phase 1 | 339 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 3 | Aug 21, 2026 | clinicaltrials |
| NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | recruiting | Phase 1 / Phase 2 | 166 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07631793 | Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors(YKYY031，tumors) | recruiting | Phase 1 | 76 | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07779031 | A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT(TP53) | active not recruiting | Phase 1 / Phase 2 | 58 | Liping DouOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04886804 | Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | active not recruiting | Phase 1 | 554 | Boehringer IngelheimINDUSTRY | 18 | Aug 20, 2026 | clinicaltrials |
| NCT05579132 | A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) | recruiting | Phase 1 / Phase 2 | 203 | MSD R&D (China) Co., Ltd.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05614739 | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3(FORAGER-1) | recruiting | Phase 1 | 677 | Eli Lilly and CompanyINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT06741644 | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 800 | CStone PharmaceuticalsINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT07636499 | Selective Neck Dissection Under Multimodal Assessment for N3 Nasopharyngeal Carcinoma After Radiotherapy | active not recruiting | Phase 1 | 50 | Guiquan ZhuOTHER | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials